The drama surrounding Sarepta's gene therapy, where a top regulator was ousted after political pushback and later reinstated, shows the FDA is now more amenable to outside influence. This case study indicates that presidential and activist pressure can directly impact regulatory enforcement and personnel decisions, moving beyond purely scientific considerations.

The biopharma industry is criticized for a "collective foresight failure," repeatedly ignoring clear political warnings like the confirmation of RFK Jr. and mass FDA firings. Instead of preemptively assessing risks, the industry waits until foundational regulatory structures collapse before raising alarms, demonstrating a reactive rather than proactive policy strategy.

Individual biotech executives are reluctant to publicly challenge the FDA because their companies have drugs under active review. Forming a broad coalition with investors and patient advocates allows them to voice concerns collectively, providing a shield against potential regulatory blowback that any single company might face if it spoke out alone.

Stelios Papadopoulos claims the biotech industry's public silence on the FDA's dysfunction stems from two core factors: a rational fear of agency retribution against their companies, and a passive hope that future political changes will magically resolve the issues.

Recent events, like Moderna's rescinded 'refusal to file' letter, reveal that alignment with FDA staff on trial design is no guarantee. Senior leaders, notably Vinay Prasad, are reportedly overturning prior agreements, creating extreme uncertainty and making it impossible for companies to trust the regulatory guidance they receive.

Author and Ovid Therapeutics Chairman Jeremy Levin identifies a dangerous paradox: while biotech science is advancing at an extraordinary rate, the system that translates science into medicine is weakening. He points to pressures on capital, regulators, and public trust as fractures in the infrastructure that made American biotech dominant.

The HHS Secretary's unprecedented interview of a candidate for FDA's CEDAR Director marks a significant politicization of a traditionally scientific, civil service position. This shift suggests future directors may need political alignment with the administration, leading to greater risk aversion, erratic decision-making, and less predictability for the biopharma industry.

An unusual alliance of investors, patient advocacy groups, and biotech executives has formed to lobby Washington about the FDA. This broad-based pushback indicates that the agency's problems are perceived as systemic, not just isolated incidents.

Industry sentiment on the FDA is not monolithic. A recent survey reveals that while biotechs largely maintain confidence in the agency's hardworking staff and their day-to-day interactions, there is deep concern and a lack of trust in the agency's top leadership. This nuanced view highlights that the perceived problems are rooted in politicization and leadership competence, not frontline operations.